{"nctId":"NCT00335738","briefTitle":"Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma","startDateStruct":{"date":"2005-12"},"conditions":["Intraocular Retinoblastoma"],"count":331,"armGroups":[{"label":"Group 1 (identified by central review as high risk)","type":"EXPERIMENTAL","interventionNames":["Drug: liposomal vincristine sulfate","Drug: carboplatin","Drug: etoposide"]},{"label":"Group 2 (identified by central review as not high risk)","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"liposomal vincristine sulfate","otherNames":["liposomal vincristine","Marqibo","vincristine liposomal","vincristine sulfate liposome injection"]},{"name":"carboplatin","otherNames":["Carboplat","CBDCA","JM-8","Paraplat","Paraplatin"]},{"name":"etoposide","otherNames":["EPEG","VP-16","VP-16-213"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Newly diagnosed unilateral retinoblastoma\n* Underwent enucleation as primary therapy within the past 5 weeks\n\n  * Must enroll and submit pathology slides within 21 days of enucleation\n  * Adjuvant chemotherapy must begin within 35 days after enucleation\n* Disease with or without high-risk histopathologic features\n\n  * High-risk features are defined as any of the following:\n\n    * Posterior uveal invasion (includes choroidal invasion)\n    * Any degree of concomitant choroid and/or optic nerve involvement\n    * Tumor involving the optic nerve posterior to the lamina cribrosa as an independent finding\n    * Scleral invasion\n    * Anterior chamber seeding\n    * Ciliary body infiltration\n    * Iris infiltration\n* No evidence of extraocular retinoblastoma clinically, by CT scan, or by MRI of the brain and orbits with and without gadolinium\n* No tumor at the cut end of the optic nerve on any eye enucleated as evidenced by histologic examination prior to study entry\n* No systemic metastases as evidenced by bone marrow scan, bone scan, or any other additional test at study entry\n* Lansky performance status 50-100%\n* Hemoglobin \\> 8 g/dL\n* Absolute neutrophil count ≥ 1,000/mm³\n* Platelet count ≥ 100,000/mm³\n* Creatinine adjusted according to age as follows:\n\n  * No greater than 0.4 mg/dL (≤ 5 months)\n  * No greater than 0.5 mg/dL (6 months -11 months)\n  * No greater than 0.6 mg/dL (1 year-23 months)\n  * No greater than 0.8 mg/dL (2 years-5 years)\n  * No greater than 1.0 mg/dL (6 years-9 years)\n  * No greater than 1.2 mg/dL (10 years-12 years)\n  * No greater than 1.4 mg/dL (13 years and over \\[female\\])\n  * No greater than 1.5 mg/dL (13 years to 15 years \\[male\\])\n  * No greater than 1.7 mg/dL (16 years and over \\[male\\])\n* Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min\n* Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age\n* AST or ALT \\< 2.5 times ULN for age\n* No prior therapy other than enucleation\n* No prior chemotherapy","healthyVolunteers":false,"sex":"ALL","maximumAge":"6 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-free Survival (EFS)","description":"EFS distributions will be estimated by the Kaplan-Meier method for patients with high risk features according to central review and treated with adjuvant chemotherapy and separately for subjects with central review recommendation of enucleation alone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9394","spread":null},{"groupId":"OG001","value":"0.9953","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS)","description":"OS distributions will be estimated by the Kaplan-Meier method for patients with high risk features according to central review and treated with adjuvant chemotherapy and separately for subjects with central review recommendation of enucleation alone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9628","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Toxicity As Assessed By the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0","description":"Number of patients assigned chemotherapy who experienced grade 3 or higher CTC AE toxicity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Pathological Features Present At Diagnosis - Posterior Uveal Invasion (PVI)","description":"Proportion of patients who had posterior uveal invasion at enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Pathological Features Present At Diagnosis - Tumor Involving the Optic Nerve Posterior to the Lamina Cribrosa (LC) as an Independent Finding","description":"Proportion of patients with tumor involving the optic nerve posterior to the lamina cribrosa as an independent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":null}]}]}]},{"type":"SECONDARY","title":"Pathological Features Present at Diagnosis - Scleral Invasion (SI)","description":"Proportion of patients that had scleral invasion at enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.016","spread":null}]}]}]},{"type":"SECONDARY","title":"Pathological Features Present At Diagnosis - Anterior Chamber Seeding (ACS)","description":"Proportion of patients who had anterior chamber seeding at enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.045","spread":null}]}]}]},{"type":"SECONDARY","title":"Pathological Features Present At Diagnosis - Iris Infiltration (II)","description":"Proportion of patients who had iris infiltration at enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.029","spread":null}]}]}]},{"type":"SECONDARY","title":"Pathological Features Present At Diagnosis - Ciliary Body Infiltration (CBI)","description":"Proportion of patients who had ciliary body infiltration at enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.019","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":93},"commonTop":["Febrile neutropenia","Neutrophil count decreased","Anaphylaxis","Platelet count decreased","Vomiting"]}}}